Stephanie Green
Primary Care · Saint Marys, GANPI 1124528237
Payments from drug & device makers
What this record shows
Almost everything reported here is food and beverage — 100.0% of the total across 283 separate payments, which is the pattern of a clinician who attends manufacturer presentations rather than one with a consulting arrangement. It is spread thinly across 35 manufacturers, the largest accounting for just 12.1% — the pattern of someone who eats at a lot of different presentations. Among primary care clinicians in GA with any reported payments, this total sits in the top 10% — high for the specialty, which is a reason to read the composition above rather than the number alone.
Across 283 payments — averaging $17.67 each. Meals, travel, consulting and speaking fees, gifts and royalties reported by drug and device makers.
- Novo Nordisk$603
- AbbVie$581
- Salix Pharmaceuticals, A Division Of Bausch Health US, LLC$346
- Lilly USA, LLC$314
- GSK$298
- Amgen$298
- plus $3K from 29 others
What the payments were for
- Food & beverage$4,999100%
Most of this is food and beverage — typically meals provided during product presentations at a clinic or hospital. Nationally that is the single largest category of reported payments by count.
General payments by program year
Who reported the general payments
Companies are grouped under their corporate parent — a single manufacturer often files under several CMS reporting entities. Research and ownership payments are counted separately and are not in this table.
| Company | Payments | Total |
|---|---|---|
| Novo Nordisk | 38 | $603 |
| AbbVie(2 entities) | 39 | $581 |
| Salix Pharmaceuticals, A Division Of Bausch Health US, LLC | 21 | $346 |
| Lilly USA, LLC | 17 | $314 |
| GSK | 16 | $298 |
| Amgen | 18 | $298 |
| Novartis | 13 | $263 |
| Johnson & Johnson | 15 | $206 |
| Astellas Pharma US Inc | 11 | $200 |
| Insulet Corporation | 9 | $198 |
| AstraZeneca | 10 | $181 |
| Otsuka America Pharmaceutical, Inc. | 9 | $180 |
| Pfizer | 8 | $173 |
| Abbott | 7 | $139 |
| Dexcom, Inc. | 8 | $119 |
| Biohaven Pharmaceutical Holding Company Ltd. | 4 | $103 |
| Biohaven Pharmaceuticals, Inc. | 3 | $89 |
| Exact Sciences | 4 | $83 |
| Boehringer Ingelheim | 5 | $78 |
| Bayer | 3 | $58 |
| Merck | 4 | $53 |
| Takeda Pharmaceuticals U.S.A., Inc. | 3 | $50 |
| Boston Scientific | 2 | $49 |
| Vertos Medical, Inc. | 1 | $47 |
| UCB, Inc. | 2 | $43 |
| Nevro Corp. | 2 | $39 |
| Medtronic | 2 | $39 |
| Phathom Pharmaceuticals, Inc. | 1 | $28 |
| Idorsia Pharmaceuticals US Inc | 2 | $28 |
| Axsome Therapeutics, Inc. | 1 | $22 |
| Sunovion Pharmaceuticals Inc. | 1 | $21 |
| Sanofi Pasteur Inc. | 1 | $21 |
| Xeris Pharmaceuticals, Inc. | 1 | $18 |
| Ferring Pharmaceuticals Inc. | 1 | $17 |
| Arbor Pharmaceuticals, Inc. | 1 | $14 |
How this compares
$4,999 in reported general payments places this provider in the 90th percentile of 235 primary care providers in Georgia.
Medicare billing
What this is not: this is the amount Original Medicare Part B allowed for services this provider billed in 2024. It is not their income. It excludes Medicare Advantage — now more than half of all Medicare enrollment — along with Medicaid and all commercial insurance, and it is gross practice revenue before staff, rent, supplies and malpractice premiums. CMS also suppresses any figure covering ten or fewer patients, so low-volume providers appear smaller than they are.
Most prescribed under Part D
| Drug | Claims | Cost to plans & patients |
|---|---|---|
| OzempicSemaglutide | 40 | $46,603 |
| JardianceEmpagliflozin | 40 | $43,786 |
| EliquisApixaban | 28 | $28,079 |
| TrulicityDulaglutide | 25 | $23,542 |
| FarxigaDapagliflozin Propanediol | 21 | $21,943 |
| JanuviaSitagliptin Phosphate | 13 | $21,742 |
| Trelegy ElliptaFluticasone/Umeclidin/Vilanter | 14 | $15,361 |
| MyrbetriqMirabegron | 19 | $11,649 |
| Breo ElliptaFluticasone/Vilanterol | 14 | $6,653 |
| Albuterol Sulfate HfaAlbuterol Sulfate | 49 | $1,794 |
| Levothyroxine Sodium | 148 | $1,614 |
| Omeprazole | 95 | $1,271 |
| Venlafaxine Hcl ErVenlafaxine Hcl | 35 | $1,205 |
| Atorvastatin Calcium | 193 | $1,108 |
| Gabapentin | 106 | $1,047 |
Paid to pharmacies, not to this prescriber.
Companies that both paid and supply prescribed drugs
These companies both reported payments to this provider and make drugs the provider prescribed under Medicare Part D in 2024. For most specialties this overlap is expected — a cardiologist who is paid by a cardiology drugmaker also treats heart disease. It is shown so the reader can see it, not because it implies anything on its own.
| Company | Paid to this provider | Part D cost of their drugs |
|---|---|---|
| Novo NordiskOzempic | $603 | $46,60340 claims |
| Boehringer IngelheimJardiance | $78 | $43,78640 claims |
| PfizerEliquis | $173 | $28,07928 claims |
| Lilly USA, LLCTrulicity | $314 | $23,54225 claims |
| GSKTrelegy Ellipta, Breo Ellipta | $298 | $22,01528 claims |
| AstraZenecaFarxiga | $181 | $21,94321 claims |
| MerckJanuvia | $53 | $21,74213 claims |
| Astellas Pharma US IncMyrbetriq | $200 | $11,64919 claims |
Reading this fairly. The Part D column is what drug plans and patients paid pharmacies — this provider received none of it, and it reflects how many patients they treat and what those drugs cost. Against peers, this provider's reported payments sit in the 90th percentile of 235 primary care providers in Georgia.
Other primary care in Saint Marys
- Pamela TurkDouglas$15K
- Morgan JonesLawrenceville$14K
- Jessi HaleColumbus$13K
- Meredith CarrAugusta$12K
- Ashtyn ZaryckiSavannah$12K
- Zanetta BryantNewnan$11K
- Hannah CummingsSuwanee$9K
- Michelle LadewigGainesville$7K
- Lucia OcanoviciuCanton$7K
- Sarah NewGrovetown$7K
Where these figures come from
- Payments: CMS Open Payments, program years 2019–2025 (publication P06302026_06032026).
- Billing: Medicare Physician & Other Practitioners, data year 2024. Original Medicare Part B only.
- Identity: NPPES NPI Registry, July 2026.